Global Cell Cryopreservation Market will register a 21.5% CAGR from 2024 to 2032 due to advancements in biobanking technologies and the expanding applications of stem cell research. With the launch of new laboratories, there’s an increased capacity for cryopreserving cells for various purposes, such as regenerative medicine, drug discovery, and tissue engineering. These developments offer opportunities for preserving valuable cell resources, driving demand. Additionally, the growing emphasis on personalized medicine and the rising adoption of stem cell-based therapies will further contribute to the market expansion.

For instance, in October 2023, OrganaBio, a contract technology development and manufacturing organization (CTDMO) focusing on cell and immunotherapy solutions, introduced a new division called Cell Processing and Cryopreservation (CPC) Services. This specialized division aims to offer decentralized clinical trial support, encompassing prompt sample processing and data capture tailored to the needs of the industry.

The cell cryopreservation market is classified based on cell type, application, and region.

The oocytes and embryotic cells segment will capture a remarkable share by 2032, driven by the increasing demand for assisted reproductive technologies (ART) and fertility preservation procedures. Oocytes and embryotic cells are crucial for in vitro fertilization (IVF) procedures and stem cell research, prompting higher adoption rates. Moreover, advancements in cryopreservation techniques have improved the viability and success rates of storing these cells, further fueling the growth of this segment in the market.

The regenerative medicine segment will achieve notable market share by 2032, fueled by the increasing applications of cryopreserved cells in regenerative therapies, tissue engineering, and stem cell research. Additionally, advancements in cryopreservation techniques, in line with growing investments in regenerative medicine research, bolster the segment’s growth. With regenerative medicine emerging as a promising field for treating various medical conditions, the demand for cryopreserved cells will surge, solidifying the segment’s leading position in the market.

Asia Pacific cell cryopreservation industry will demonstrate a significant CAGR from 2024 to 2032, attributed to several factors, including the increasing prevalence of chronic diseases, rising healthcare expenditure, and growing awareness about the benefits of stem cell therapy. Moreover, the region’s expanding biotechnology and pharmaceutical industries, in tandem with supportive government initiatives, will contribute to market growth. With a large population base and improving healthcare infrastructure, Asia Pacific will maintain its prominence in the cell cryopreservation market.